Key Highlights

  • Loss per share was USD 0.12, matching an estimate of a USD 0.12 loss.
  • Net loss was USD 7.18 million, against USD 8.90 million a year earlier.
  • Research and development expenses were USD 5.34 million, against USD 6.36 million.
  • Grant income was USD 310 thousand in the quarter.

MAIA Biotechnology (NYSE American:MAIA) reported a third quarter 2026 loss per share of USD 0.12, matching an estimate of a USD 0.12 loss and compared with a USD 0.27 loss in the third quarter of 2025. Net loss was USD 7.18 million, compared with USD 8.90 million.

The loss from operations was USD 8.02 million, compared with USD 9.36 million. The company reported the figures in its quarterly filing for the period ended September 30, 2026.

Operating Expenses and Other Income

Research and development expenses were USD 5.34 million, compared with USD 6.36 million. General and administrative expenses were USD 2.69 million, compared with USD 3.00 million. Total operating expenses were USD 8.02 million, compared with USD 9.36 million.

Interest income was USD 186 thousand, compared with USD 78 thousand. The company reported grant income of USD 310 thousand, and a change in Fair Value of its Warrant Liability of USD 350 thousand, compared with USD 379 thousand.

Nine-Month Results

For the nine months ended September 30, 2026, net loss was USD 21.49 million, compared with USD 18.77 million, and the loss per share was USD 0.39, against USD 0.62. Total operating expenses were USD 23.29 million, against USD 19.95 million.

Research and development expenses for the nine months were USD 14.50 million, against USD 12.67 million, and general and administrative expenses were USD 8.79 million, against USD 7.29 million. Interest income for the nine months was USD 534 thousand and grant income was USD 731 thousand.

Going Concern and Program Description

The filing states that, based on cost control measures implemented, management believes the substantial doubt about the company's ability to continue as a Going Concern for at least 12 months from the date the financial statements were issued is reasonably alleviated. It also states that the company needs to raise additional Capital to fund operations, to develop and commercialize ateganosine, and to develop, acquire or in-license other products.

The filing describes the Phase 2 THIO-101 trial of ateganosine in Australia, and a trial named THIO-104 evaluating ateganosine administered in sequence with a checkpoint inhibitor in third-line non-small cell lung cancer patients who are resistant to checkpoint inhibitors and chemotherapy.

The filing also states that advance payments for goods and services to be used in future Research and Development activities are expensed when the activity has been performed or the goods have been received, and that the company bases research expense related to contract research organizations and contract manufacturers on estimates of services received.

MAIA Biotechnology Q3 2026 Earnings: Key Takeaways

MAIA Biotechnology reported a third quarter 2026 loss per share of USD 0.12 and a net loss of USD 7.18 million. Research and development expenses were USD 5.34 million, and total operating expenses were USD 8.02 million.